Technetium Tc 99m Tilmanocept

The Basics

What is Technetium Tc 99m Tilmanocept?

A radioactive diagnostic agent.

Brand names for Technetium Tc 99m Tilmanocept

Mdp Multidose Kit

How Technetium Tc 99m Tilmanocept is classified

Radiopharmaceuticals, Technetium Radioisotopes, Diagnostic Agents

Technetium Tc 99m Tilmanocept During Pregnancy

Technetium Tc 99m Tilmanocept pregnancy category

Category CNote that the FDA has deprecated the use of pregnancy categories, so for some medications, this information isn’t available. We still think it’s useful to list historical info, however, given what a common proxy this has been in the past.

What we know about taking Technetium Tc 99m Tilmanocept while pregnant

Animal reproduction studies have not been conducted with technetium Tc99m medronate injection. It is also not known whether technetium Tc99m medronate injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Technetium Tc99m medronate injection should be given to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability, should be performed during the first few (approximately 10) days following the onset of menses.

Taking Technetium Tc 99m Tilmanocept While Breastfeeding

What are recommendations for lactation if you're taking Technetium Tc 99m Tilmanocept?

Information in this record refers to the use of technetium Tc 99m tilmanocept as a diagnostic agent. No information is available on the use of technetium Tc 99m tilmanocept during breastfeeding. The manufacturer recommends withholding breastfeeding for 60 hours after a diagnostic dose. This length of time is 10 half-lives of the radioisotope, so the nursing infant should not be exposed to radiation if this guideline is followed. However, the effective half-life is 1.8 to 3.1 hours, indicating that resumption of breastfeeding after 30 hours should ensure that the infant is not exposed to any radioactivity via breastmilk. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1][2][3] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or stored frozen and given to the infant after 10 physical half-lives, or about 60 hours, have elapsed. Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[4] For nursing mothers who work with Tc 99m substances in their workplace, there is no need to take any precautions other than those appropriate for general radiation protection.[5]

Maternal / infant drug levels

Information in this record refers to the use of technetium Tc 99m tilmanocept as a diagnostic agent. No information is available on the use of technetium Tc 99m tilmanocept during breastfeeding. The manufacturer recommends withholding breastfeeding for 60 hours after a diagnostic dose. This length of time is 10 half-lives of the radioisotope, so the nursing infant should not be exposed to radiation if this guideline is followed. However, the effective half-life is 1.8 to 3.1 hours, indicating that resumption of breastfeeding after 30 hours should ensure that the infant is not exposed to any radioactivity via breastmilk. The mother can nurse just before administration of the radiopharmaceutical. If the mother has expressed and saved milk prior to the examination, she can feed it to the infant during the period of nursing interruption.[1][2][3] The milk that is pumped by the mother during the time of breastfeeding interruption can either be discarded or stored frozen and given to the infant after 10 physical half-lives, or about 60 hours, have elapsed. Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[4] For nursing mothers who work with Tc 99m substances in their workplace, there is no need to take any precautions other than those appropriate for general radiation protection.[5]

Possible effects of Technetium Tc 99m Tilmanocept on milk supply

Relevant published information was not found as of the revision date.

Possible alternatives to Technetium Tc 99m Tilmanocept